# A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

> **NCT03926130** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1158 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Mirikizumab
- **DRUG:** Ustekinumab
- **DRUG:** Ustekinumab
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03926130
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-10-02
- **Target enrollment:** 1158 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926130, "A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03926130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*